ROR1 and ROR2 in human malignancies: Potentials for targeted therapy

Frontiers in Oncology

Volumn 2, Issue APR, 2012, Pages

  Rebagay, Guilly ^a,b   Yan, Su ^c   Liu, Cheng ^c   Cheung, Nai Kong ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b MEDICAL COLLEGE OF GEORGIA   (United States)

^c EUREKA THERAPEUTICS   (United States)

Author keywords

Immunotherapy; Receptor tyrosine kinase orphan receptors (ROR1 ROR2); Solid tumor; Wnt beta catenin

Indexed keywords

DASATINIB; MONOCLONAL ANTIBODY; RECEPTOR TYROSINE KINASE LIKE ORPHAN RECEPTOR; RITUXIMAB;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; APOPTOSIS; AUTOPHOSPHORYLATION; CARCINOGENESIS; CELL INVASION; CELL MIGRATION; CHRONIC LYMPHATIC LEUKEMIA; HUMAN; MINIMAL RESIDUAL DISEASE; NEOPLASM; NEUROBLASTOMA; NONHUMAN; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REVIEW; SIGNAL TRANSDUCTION;

EID: 84869065974     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2012.00034     Document Type: Review

References (63)

1. Afzal, A. R., and Jeffery, S. (2003). One gene, two phenotypes: ROR2 mutations in autosomal recessive Robinow syndrome and autosomal dominant brachydactyly type B. Hum. Mutat. 22, 1-11.
2. Afzal, A. R., Rajab, A., Fenske, C. D., Oldridge, M., Elanko, N., Ternes-Pereira, E., Tuysuz, B., Murday, V. A., Patton, M. A., Wilkie, A. O., and Jeffery, S. (2000). Recessive Robinow syndrome, allelic to dominant brachydactyly type B, is caused by mutation of ROR2. Nat. Genet. 25, 419-422.
3. Al-Shawi, R., Ashton, S. V., Underwood, C., and Simons, J. P. (2001). Expression of the Ror1 and Ror2 receptor tyrosine kinase genes during mouse development. Dev. Genes Evol. 211, 161-171.
4. Asgharzadeh, S., Pique-Regi, R., Sposto, R., Wang, H., Yang, Y., Shimada, H., Matthay, K., Buckley, J., Ortega, A., and Seeger, R. C. (2006). Prognostic significance of gene expression profiles of metastatic neuroblastomas lacking MYCN gene amplification. J. Natl. Cancer Inst. 98, 1193-1203.
5. Bargou, R., Leo, E., Zugmaier, G., Klinger, M., Goebeler, M., Knop, S., Noppeney, R., Viardot, A., Hess, G., Schuler, M., Einsele, H., Brandl, C., Wolf, A., Kirchinger, P., Klappers, P., Schmidt, M., Riethmuller, G., Reinhardt, C., Baeuerle, P. A., and Kufer, P. (2008). Tumor regression in cancer patients by very low doses of a T cell-engaging antibody. Science 321, 974-977.
6. Barna, G., Mihalik, R., Timar, B., Tombol, J., Csende, Z., Sebestyen, A., Bodor, C., Csernus, B., Reiniger, L., Petak, I., and Matolcsy, A. (2011). ROR1 expression is not a unique marker of CLL. Hematol. Oncol. 29, 17-21.
7. Baskar, S., Kwong, K. Y., Hofer, T., Levy, J. M., Kennedy, M. G., Lee, E., Staudt, L. M., Wilson, W. H., Wiestner, A., and Rader, C. (2008). Unique cell surface expression of receptor tyrosine kinase ROR1 in human B-cell chronic lymphocytic leukemia. Clin. Cancer Res. 14, 396-404.
8. Bicocca, V. T., Chang, B. H., Muschen, M., Druker, B. J., and Tyner, J. W. (2011). "Compensatory signaling from ROR1 and the pre-B cell receptor promote survival of t(1;19) acute lymphoblastic leukemia blood," in ASH Annual Meeting Abstracts, San Diego, Vol. 118, :2466.
9. Blanc, E., Roux, G. L., Benard, J., and Raguenez, G. (2005). Low expression of Wnt-5a gene is associated with high-risk neuroblastoma. Oncogene 24, 1277-1283.
10. Bowden, E. T., Barth, M., Thomas, D., Glazer, R. I., and Mueller, S. C. (1999). An invasion-related complex of cortactin, paxillin and PKCmu associates with invadopodia at sites of extracellular matrix degradation. Oncogene 18, 4440-4449.
11. Choi, B. D., Cai, M., Bigner, D. D., Mehta, A. I., Kuan, C. T., and Sampson, J. H. (2011). Bispecific antibodies engage T cells for antitumor immunotherapy. Expert Opin. Biol. Ther. 11, 843-853.
12. Choudhury, A., Derkow, K., Daneshmanesh, A. H., Mikaelsson, E., Kiaii, S., Kokhaei, P., Osterborg, A., and Mellstedt, H. (2010). Silencing of ROR1 and FMOD with siRNA results in apoptosis of CLL cells. Br. J. Haematol. 151, 327-335.
13. Cui, B., Widhopf, G. F. II., Martinez, J. Y. D., Avery, E., Zhang, S., Chen, L., Wu, R., Wu, C. C. N., Prussak, C., and Kipps, T. J. (2011). "Targeting of chronic lymphocytic leukemia B cells with a novel monoclonal antibody to ror1 blood," in ASH Annual Meeting Abstracts, San Diego, Vol. 118, :984.
14. Daneshmanesh, A. H., Hojjat-Farsangi, M., Khan, A. S., Jeddi-Tehrani, M., Akhondi, M. M., Bayat, A. A., Ghods, R., Mahmoudi, A. R., Hadavi, R., Osterborg, A., Shokri, F., Rabbani, H., and Mellstedt, H. (2012). Monoclonal antibodies against ROR1 induce apoptosis of chronic lymphocytic leukemia (CLL) cells. Leukemia. doi:10.1038/leu.2011.362. [Epub ahead of print].
15. Daneshmanesh, A. H., Mikaelsson, E., Jeddi-Tehrani, M., Bayat, A. A., Ghods, R., Ostadkarampour, M., Akhondi, M., Lagercrantz, S., Larsson, C., Osterborg, A., Shokri, F., Mellstedt, H., and Rabbani, H. (2008). Ror1, a cell surface receptor tyrosine kinase is expressed in chronic lymphocytic leukemia and may serve as a putative target for therapy. Int. J. Cancer 123, 1190-1195.
16. Edris, B., Espinosa, I., Mühlenberg, T., Mikels, A., Lee, C. H., Steigen, S. E., Zhu, S., Montgomery, K. D., Lazar, A. J., Lev, D., Fletcher, J. A., Beck, A. H., West, R. B., Nusse, R., and van de Rijn, M. (2012). ROR2 is a novel prognostic biomarker and a potential therapeutic target in leiomyosarcoma and gastrointestinal stromal tumour. J. Pathol. doi:10.1002/path.3986. [Epub ahead of print].
17. Enomoto, M., Hayakawa, S., Itsukushima, S., Ren, D. Y., Matsuo, M., Tamada, K., Oneyama, C., Okada, M., Takumi, T., Nishita, M., and Minami, Y. (2009). Autonomous regulation of osteosarcoma cell invasiveness by Wnt5a/Ror2 signaling. Oncogene 28, 3197-3208.
18. Forrester, W. C., Dell, M., Perens, E., and Garriga, G. (1999). A C. elegans Ror receptor tyrosine kinase regulates cell motility and asymmetric cell division. Nature 400, 881-885.
19. Fukuda, T., Chen, L., Endo, T., Tang, L., Lu, D., Castro, J. E., Widhopf, G. F. II, Rassenti, L. Z., Cantwell, M. J., Prussak, C. E., Carson, D. A., and Kipps, T. J. (2008). Antisera induced by infusions of autologous Ad-CD154-leukemia B cells identify ROR1 as an oncofetal antigen and receptor for Wnt5a. Proc. Natl. Acad. Sci. U.S.A. 105, 3047-3052.
20. Gentile, A., Lazzari, L., Benvenuti, S., Trusolino, L., and Comoglio, P. M. (2011). Ror1 is a pseudokinase that is crucial for Met-driven tumorigenesis. Cancer Res. 71, 3132-3141.
21. Green, J. L., Inoue, T., and Sternberg, P. W. (2007). The C. elegans ROR receptor tyrosine kinase, CAM-1, non-autonomously inhibits the Wnt pathway. Development 134, 4053-4062.
22. Green, J. L., Kuntz, S. G., and Sternberg, P. W. (2008). Ror receptor tyrosine kinases: orphans no more. Trends Cell Biol. 18, 536-544.
23. Hudecek, M., Schmitt, T. M., Baskar, S., Lupo-Stanghellini, M. T., Nishida, T., Yamamoto, T. N., Bleakley, M., Turtle, C. J., Chang, W. C., Greisman, H. A., Wood, B., Maloney, D. G., Jensen, M. C., Rader, C., and Riddell, S. R. (2010). The B-cell tumor-associated antigen ROR1 can be targeted with T cells modified to express a ROR1-specific chimeric antigen receptor. Blood 116, 4532-4541.
24. Ishitani, T., Kishida, S., Hyodo-Miura, J., Ueno, N., Yasuda, J., Waterman, M., Shibuya, H., Moon, R. T., Ninomiya-Tsuji, J., and Matsumoto, K. (2003). The TAK1-NLK mitogen-activated protein kinase cascade functions in the Wnt-5a/Ca(2+) pathway to antagonize Wnt/beta-catenin signaling. Mol. Cell. Biol. 23, 131-139.
25. Kani, S., Oishi, I., Yamamoto, H., Yoda, A., Suzuki, H., Nomachi, A., Iozumi, K., Nishita, M., Kikuchi, A., Takumi, T., and Minami, Y. (2004). The receptor tyrosine kinase Ror2 associates with and is activated by casein kinase Iepsilon. J. Biol. Chem. 279, 50102-50109.
26. Katoh, M. (2005). Comparative genomics on ROR1 and ROR2 orthologs. Oncol. Rep. 14, 1381-1384.
27. Kaucka, M., Krejci, P., Plevova, K., Pavlova, S., Prochazkova, J., Janovska, P., Valnohova, J., Kozubik, A., Pospisilova, S., and Bryja, V. (2011). Post-translational modifications regulate signalling by Ror1. Acta Physiol. (Oxf). 203, 351-362.
28. Kobayashi, M., Shibuya, Y., Takeuchi, J., Murata, M., Suzuki, H., Yokoo, S., Umeda, M., Minami, Y., and Komori, T. (2009). Ror2 expression in squamous cell carcinoma and epithelial dysplasia of the oral cavity. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod. 107, 398-406.
29. Kurban, G., Hudon, V., Duplan, E., Ohh, M., and Pause, A. (2006). Characterization of a von Hippel Lindau pathway involved in extracellular matrix remodeling, cell invasion, and angiogenesis. Cancer Res. 66, 1313-1319.
30. Li, P., Harris, D., Liu, Z., Liu, J., Keating, M., and Estrov, Z. (2010). Stat3 activates the receptor tyrosine kinase like orphan receptor-1 gene in chronic lymphocytic leukemia cells. PLoS ONE 5, e11859. doi:10.1371/journal.pone.0011859
31. Liu, Y., Rubin, B., Bodine, P. V., and Billiard, J. (2008). Wnt5a induces homodimerization and activation of Ror2 receptor tyrosine kinase. J. Cell. Biochem. 105, 497-502.
32. Lyashenko, N., Weissenböck, M., Sharir, A., Erben, R. G., Minami, Y., and Hartmann, C. (2010). Mice lacking the orphan receptor ror1 have distinct skeletal abnormalities and are growth retarded. Dev. Dyn. 239, 2266-2277.
33. Maeda, K., Kobayashi, Y., Udagawa, N., Uehara, S., Ishihara, A., Mizoguchi, T., Kikuchi, Y., Takada, I., Kato, S., Kani, S., Nishita, M., Marumo, K., Martin, T. J., Minami, Y., and Takahashi, N. (2012). Wnt5a-Ror2 signaling between osteoblast-lineage cells and osteoclast precursors enhances osteoclastogenesis. Nat. Med. 18, 405-12.
34. Masiakowski, P., and Carroll, R. D. (1992). A novel family of cell surface receptors with tyrosine kinase-like domain. J. Biol. Chem. 267, 26181-26190.
35. McDonald, S. L., and Silver, A. (2009). The opposing roles of Wnt-5a in cancer. Br. J. Cancer 101, 209-214.
36. Mikels, A., Minami, Y., and Nusse, R. (2009). Ror2 receptor requires tyrosine kinase activity to mediate Wnt5A signaling. J. Biol. Chem. 284, 30167-30176.
37. Mikels, A. J., and Nusse, R. (2006). Purified Wnt5a protein activates or inhibits beta-catenin-TCF signaling depending on receptor context. PLoS Biol. 4, e115. doi:10.1371/journal.pbio.0040115
38. Minami, Y., Oishi, I., Endo, M., and Nishita, M. (2010). Ror-family receptor tyrosine kinases in noncanonical Wnt signaling: their implications in developmental morphogenesis and human diseases. Dev. Dyn. 239, 1-15.
39. Morioka, K., Tanikawa, C., Ochi, K., Daigo, Y., Katagiri, T., Kawano, H., Kawaguchi, H., Myoui, A., Yoshikawa, H., Naka, N., Araki, N., Kudawara, I., Ieguchi, M., Nakamura, K., Nakamura, Y., and Matsuda, K. (2009). Orphan receptor tyrosine kinase ROR2 as a potential therapeutic target for osteosarcoma. Cancer Sci. 100, 1227-1233.
40. Nomachi, A., Nishita, M., Inaba, D., Enomoto, M., Hamasaki, M., and Minami, Y. (2008). Receptor tyrosine kinase Ror2 mediates Wnt5a-induced polarized cell migration by activating c-Jun N-terminal kinase via actin-binding protein filamin A. J. Biol. Chem. 283, 27973-27981.
41. Nomi, M., Oishi, I., Kani, S., Suzuki, H., Matsuda, T., Yoda, A., Kitamura, M., Itoh, K., Takeuchi, S., Takeda, K., Akira, S., Ikeya, M., Takada, S., and Minami, Y. (2001). Loss of mRor1 enhances the heart and skeletal abnormalities in mRor2-deficient mice: redundant and pleiotropic functions of mRor1 and mRor2 receptor tyrosine kinases. Mol. Cell. Biol. 21, 8329-8335.
42. O'Connell, M. P., Fiori, J. L., Xu, M., Carter, A. D., Frank, B. P., Camilli, T. C., French, A. D., Dissanayake, S. K., Indig, F. E., Bernier, M., Taub, D. D., Hewitt, S. M., and Weeraratna, A. T. (2010). The orphan tyrosine kinase receptor, ROR2, mediates Wnt5A signaling in metastatic melanoma. Oncogene 29, 34-44.
43. Oishi, I., Suzuki, H., Onishi, N., Takada, R., Kani, S., Ohkawara, B., Koshida, I., Suzuki, K., Yamada, G., Schwabe, G. C., Mundlos, S., Shibuya, H., Takada, S., and Minami, Y. (2003). The receptor tyrosine kinase Ror2 is involved in non-canonical Wnt5a/JNK signalling pathway. Genes Cells 8, 645-654.
44. Oishi, I., Takeuchi, S., Hashimoto, R., Nagabukuro, A., Ueda, T., Liu, Z. J., Hatta, T., Akira, S., Matsuda, Y., Yamamura, H., Otani, H., and Minami, Y. (1999). Spatio-temporally regulated expression of receptor tyrosine kinases, mRor1, mRor2, during mouse development: implications in development and function of the nervous system. Genes Cells 4, 41-56.
45. Rabbani, H., Ostadkarampour, M., Danesh Manesh, A. H., Basiri, A., Jeddi-Tehrani, M., and Forouzesh, F. (2010). Expression of ROR1 in patients with renal cancer-a potential diagnostic marker. Iran. Biomed. J. 14, 77-82.
46. Reddy, U. R., Phatak, S., Allen, C., Nycum, L. M., Sulman, E. P., White, P. S., and Biegel, J. A. (1997). Localization of the human Ror1 gene (NTRKR1) to chromosome 1p31-p32 by fluorescence in situ hybridization and somatic cell hybrid analysis. Genomics 41, 283-285.
47. Reddy, U. R., Phatak, S., and Pleasure, D. (1996). Human neural tissues express a truncated Ror1 receptor tyrosine kinase, lacking both extracellular and transmembrane domains. Oncogene 13, 1555-1559.
48. Rehn, M., Pihlajaniemi, T., Hofmann, K., and Bucher, P. (1998). The frizzled motif: in how many different protein families does it occur? Trends Biochem. Sci. 23, 415-417.
49. Sadowski, I., Stone, J. C., and Pawson, T. (1986). A noncatalytic domain conserved among cytoplasmic protein-tyrosine kinases modifies the kinase function and transforming activity of Fujinami sarcoma virus P130gag-fps. Mol. Cell. Biol. 6, 4396-4408.
50. Sato, A., Yamamoto, H., Sakane, H., Koyama, H., and Kikuchi, A. (2010). Wnt5a regulates distinct signalling pathways by binding to Frizzled2. EMBO J. 29, 41-54.
51. Schwabe, G. C., Tinschert, S., Buschow, C., Meinecke, P., Wolff, G., Gillessen-Kaesbach, G., Oldridge, M., Wilkie, A. O., Kömec, R., and Mundlos, S. (2000). Distinct mutations in the receptor tyrosine kinase gene ROR2 cause brachydactyly type B. Am. J. Hum. Genet. 67, 822-31.
52. Shabani, M., Asgarian-Omran, H., Vossough, P., Sharifian, R. A., Faranoush, M., Ghragozlou, S., Khoshnoodi, J., Roohi, A., Jeddi-Tehrani, M., Mellstedt, H., Rabbani, H., and Shokri, F. (2008). Expression profile of orphan receptor tyrosine kinase (ROR1) and Wilms' tumor gene 1 (WT1) in different subsets of B-cell acute lymphoblastic leukemia. Leuk. Lymphoma 49, 1360-1367.
53. Tassev, D. V., Cheng, M., and Cheung, N. K. (2012). Retargeting NK92 cells using an HLA-A2-restricted EBNA3C-specific chimeric antigen receptor. Cancer Gene Ther. 19, 84-100.
54. Uhrmacher, S., Schmidt, C., Erdfelder, F., Poll-Wolbeck, S. J., Gehrke, I., Hallek, M., and Kreuzer, K. A. (2011). Use of the receptor tyrosine kinase-like orphan receptor 1 (ROR1) as a diagnostic tool in chronic lymphocytic leukemia (CLL). Leuk. Res. 35, 1360-1366.
55. van Bokhoven, H., Celli, J., Kayserili, H., van Beusekom, E., Balci, S., Brussel, W., Skovby, F., Kerr, B., Percin, E. F., Akarsu, N., and Brunner, H. G. (2000). Mutation of the gene encoding the ROR2 tyrosine kinase causes autosomal recessive Robinow syndrome. Nat. Genet. 25, 423-426.
56. Vidal, M., Gigoux, V., and Garbay, C. (2001). SH2 and SH3 domains as targets for anti-proliferative agents. Crit. Rev. Oncol. Hematol. 40, 175-186.
57. Weaver, A. M. (2006). Invadopodia: specialized cell structures for cancer invasion. Clin. Exp. Metastasis 23, 97-105.
58. Wilson, C., Goberdhan, D. C., and Steller, H. (1993). Dror, a potential neurotrophic receptor gene, encodes a Drosophila homolog of the vertebrate Ror family of Trk-related receptor tyrosine kinases. Proc. Natl. Acad. Sci. U.S.A. 90, 7109-7113.
59. Wright, T. M., Brannon, A. R., Gordan, J. D., Mikels, A. J., Mitchell, C., Chen, S., Espinosa, I., Van De Rijn, M., Pruthi, R., Wallen, E., Edwards, L., Nusse, R., and Rathmell, W. K. (2009). Ror2, a developmentally regulated kinase, promotes tumor growth potential in renal cell carcinoma. Oncogene 28, 2513-2523.
60. Yamamoto, H., Yoo, S. K., Nishita, M., Kikuchi, A., and Minami, Y. (2007). Wnt5a modulates glycogen synthase kinase 3 to induce phosphorylation of receptor tyrosine kinase Ror2. Genes Cells 12, 1215-1223.
61. Yang, J., Baskar, S., Kwong, K. Y., Kennedy, M. G., Wiestner, A., and Rader, C. (2011). Therapeutic potential and challenges of targeting receptor tyrosine kinase ROR1 with monoclonal antibodies in B-cell malignancies. PLoS ONE 6, e21018. doi:10.1371/journal.pone.0021018
62. Yoda, A., Oishi, I., and Minami, Y. (2003). Expression and function of the Ror-family receptor tyrosine kinases during development: lessons from genetic analyses of nematodes, mice, and humans. J. Recept. Signal Transduct. Res. 23, 1-15.
63. Zhang, S., Chen, L., Cui, B., Chuang, H. Y., Yu, J., Wang-Rodriguez, J., Tang, L., Chen, G., Basak, G. W., and Kipps, T. J. (2012). ROR1 is expressed in human breast cancer and associated with enhanced tumor-cell growth. PLoS ONE 7, e31127. doi:10.1371/journal.pone.0031127